Catabasis Pharmaceuticals has commenced a Phase I study of CAT-2003 for the treatment of severe hypertriglyceridemia in healthy volunteers and in adults with mildly elevated lipids.
The randomised study will assess the safety, tolerability and pharmacokinetics of CAT-2003, a conjugate of niacin and eicosapentaenoic acid (EPA) covalently linked using the company’s Smart Linker technology to form a new chemical entity.
Go deeper with GlobalData
"In preclinical animal models, CAT-2003 produced robust triglyceride and low density lipoprotein (LDL) cholesterol lowering, and synergistic reductions in LDL cholesterol when CAT-2003 was combined with a statin," Jirousek said.
The results from the placebo-controlled study, which will be conducted in two parts, are expected in the second quarter of 2013.
Healthy adults will be administered with a single ascending dose of CAT-2003 or placebo in the first part of the study.
See Also:
In the second part, CAT-2003 or placebo will be administered each day for 14 days in healthy adults or patients with mildly elevated lipids.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe double-blind study will also assess triglycerides, LDL cholesterol and biomarkers related to the mechanism of action of CAT-2003.
CAT-2003 demonstrated a significant and dose-dependent reduction in plasma triglycerides in preclinical models of severe hypertriglyceridemia and LDL cholesterol reduction in preclinical models of dyslipidemia.
